The FDA just approved Janssen's new version of antipsychotic paliperidone, Invega Hafyera, whose trade name (phonetically speaking?) reminds us of its claimed duration of action of six months. I would love to have witnessed the discussions over whether to use such a silly product name, hearing all the arguments for and against.
There's nothing funny about schizophrenia. For this drug to last half a year will increase its value to many, maybe even saving lives. Even those who suffer from the disorder have a sense of humor. I hope they all get a big chuckle out of this name.
Good on Janssen for having the courage to use this name.
Berry Edwards, MD